There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Knee Arthroplasty Activity Trial
NCT04107649
Recruiting
Total knee replacement (TKR) is a common and costly procedure widely used to relieve pain and improve function in patients with symptomatic advanced knee osteoarthritis (OA). As of 2013, the annual incidence of TKR was over 680,000 surgeries and annual costs exceeded $11 billion. Growing evidence suggests that while pain and functional status improve following TKR, physical activity (PA) typically does not surpass pre-TKR levels. Engagement in PA can meaningfully improve quality of life (QoL), p... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
04/15/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Knee Osteoarthritis, Total Knee Replacement
Register for Updates
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT04294927
Recruiting
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Gender:
FEMALE
Ages:
Between 25 years and 50 years
Trial Updated:
04/15/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Register for Updates
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718
Recruiting
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of c... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Register for Updates
Quality of Pediatric Resuscitation in a Multicenter Collaborative
NCT02708134
Recruiting
This is a prospective, observational, multi-center cohort study of pediatric cardiac arrests. The purpose of the study is to determine the association between chest compression mechanics (rate, depth, flow fraction, compression release) and patient outcomes. In addition, the investigators will determine the association of post cardiac arrest care with patient outcomes.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Cardiac Arrest, Cardiopulmonary Arrest
Register for Updates
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03091257
Recruiting
This research study is studying a targeted therapy as a possible treatment for multiple myeloma. The names of the study drugs involved in this study are: * Trametinib * Dabrafenib
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates
Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma
NCT04701918
Recruiting
This research study is examining the effectiveness of pembrolizumab plus cryoablation or aveluma plus cryoablation on people with urothelial carcinoma, including bladder cancer, that has spread.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer
Register for Updates
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
NCT05952583
Recruiting
Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/12/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Twin; Pregnancy, Affecting Fetus or Newborn, Fetal Growth Retardation, Twin Monochorionic Diamniotic Placenta, Twin Diseases
Register for Updates
STIMIT Activator 1 IDE Pivotal Study
NCT05883163
Recruiting
The study is a prospective, multi-center, randomized, controlled study using adaptive design to assess the evidence of safety and performance of the STIMIT Activator 1 System in the treatment of patients who have been mechanically ventilated for up to 48 hours and are predicted to require additional minimum 48 hours of mechanical ventilation or longer (adding up to MV time approximately 96 hours or longer).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/11/2024
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Diaphragm Issues
Register for Updates
Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis
NCT06216704
Recruiting
The investigators will be evaluating bone marrow composition via magnetic resonance imaging in adolescents diagnosed with cystic fibrosis (CF) compared to healthy, matched controls. The investigators will also be assessing their bone mineral density via other imaging modalities, including dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). This longitudinal project will focus on abnormalities in bone marrow composition, and specifically whether adolesce... Read More
Gender:
ALL
Ages:
Between 13 years and 20 years
Trial Updated:
04/11/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Cystic Fibrosis
Register for Updates
Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831
Recruiting
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe crohn's disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +1 locations
Conditions: Crohn Disease
Register for Updates
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
NCT04400266
Recruiting
Traumatic brain injuries (TBIs) are common. Post-TBI depression is associated with anxiety, aggression, fatigue, distractibility, anger, irritability, and rumination. The current research group conducted a pilot clinical trial, which investigated the novel treatment combination of buspirone and melatonin (B+MEL) in outpatients with clinical depression. Compared to placebo, B+MEL was associated with a significant improvement in depressive symptoms. Depression following TBI may be different from c... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/09/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Depression, Brain Injuries, Traumatic
Register for Updates
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
NCT05519293
Recruiting
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer
Register for Updates